PRJNA764060
How a next generation probiotic may improve metabolic health; example of Faecalibacterium prausnitzii CNCM I-4573 in High Fat Diet obese mice
In the last four decades, obesity and related metabolic syndromes (type 2 diabetes, cardiovascular diseases and cancers) significantly increased worldwide.In 2016, the world health organization (WHO) estimated to 650 million obese people worldwide (representing 13% of total population).Furthermore, 2.8 million of deaths are linked to obesity each year (OMS, 2017).Obesity is a multifactorial disease, but environmental factors are highlighted with a dysbalance between energy intake and calories loss.A growing interest has emerged to better understand factors influencing development and progression of metabolic diseases.F. prausnitzii is a butyrate-producer.Several reports showed a reduction of F. prausnitzii in clinical studies relating about ulcerative colitis (UC), colorectal cancer and Crohn's disease (CD) making it a potent biomarker of gut-associated disorders.Thus, pre-clinical interventions using F. prausnitzii as probiotic were carried out and demonstrated promising strategy in inflammatory bowel diseases (IBD).More recently, F. prausnitzii level has been anticorrelated to insulin resistance and inflammatory markers in obese patients.An in vivo study in high fat diet (HFD) model revealed adipose tissue inflammation and hepatic health improvement with F. prausnitzii treatment.Here, the capacity to reduce body weight gain and linked metabolic parameters of the F. prausnitzii CNCM I-4573 strain have been assessed in HFD murine model.